Phase 3 Clinical Trials With Primary Completion Dates in August 2026
This is a list of Phase 3 trials with primary completion dates in August 2026 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AKBA | Akebia Therapeutics, Inc. | 2026-08-01 | Phase 3 | NCT06901505 | To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis |
| DFTX | Definium Therapeutics, Inc. | 2026-08-01 | Phase 3 | NCT06809595 | A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) |
| ENSC | Ensysce Biosciences, Inc. | 2026-08-01 | Phase 3 | NCT06602271 | PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301) |
| EYPT | EyePoint, Inc. | 2026-08-01 | Phase 3 | NCT06668064 | A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 |
| GRFS | Grifols, S.A. | 2026-08-01 | Phase 3 | NCT01983241 | Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD) |
| IVVD | Invivyd, Inc. | 2026-08-01 | Phase 3 | NCT07298434 | Study of VYD2311 for the Prevention of COVID-19 |
| IVVD | Invivyd, Inc. | 2026-08-01 | Phase 3 | NCT07655180 | Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine |
| KOD | Kodiak Sciences Inc. | 2026-08-01 | Phase 3 | NCT06556368 | A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK |
| KPTI | Karyopharm Therapeutics Inc. | 2026-08-01 | Phase 3 | NCT05611931 | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma |
| LLY | Eli Lilly and Company | 2026-08-01 | Phase 3 | NCT06260722 | Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) |
| MIRM | Mirum Pharmaceuticals, Inc. | 2026-08-01 | Phase 3 | NCT07298330 | A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) |
| MRCHF | H.U. Group Holdings, Inc. | 2026-08-01 | Phase 3 | NCT05040464 | Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial |
| PHVS | Pharvaris N.V. | 2026-08-01 | Phase 3 | NCT06669754 | Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE |
| RCUS | Arcus Biosciences, Inc. | 2026-08-01 | Phase 3 | NCT05568095 | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body |
| SLGL | Sol-Gel Technologies Ltd. | 2026-08-01 | Phase 3 | NCT06050122 | Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome |
| XENE | Xenon Pharmaceuticals Inc. | 2026-08-01 | Phase 3 | NCT06775379 | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder |